Out-of-pocket expenses for myasthenia gravis patients in China: a study on patients insured by basic medical insurance in China, 2013 –2015

This study analyzed the change in trends of total medica...
Source: Orphanet Journal of Rare Diseases - Category: Internal Medicine Authors: Tags: Research Source Type: research

Related Links:

Conclusion: Taken together, these results suggest that SXD maybe alleviate EMT in DN via the inhibition of the TGF-β1/Smad/RUNX3 signaling pathway under hyperglycemic conditions.Graphical abstract
Source: Phytomedicine - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 21 February 2020Source: Carbohydrate PolymersAuthor(s): Jun Zhang, Zewen Mei, Xingxi Huang, Yueyue Ding, Yunxiang Liang, Yuxia MeiAbstractA low-molecular-weight chitosan (LMWC) sample was prepared by enzymatic hydrolysis, and used for investigation of special Maillard reaction products (MRPs) and factors affecting LMWC bioactivities. After undergoing MR, LMWC turned to brown color (termed BLMWC), showed reduction of several indices of rice growth promotion. This alteration of bioactivities was attributable to MRPs in BLMWC. A special MRP, 5-hydroxy-2-pyridine methanol isomer (5-H-2PMIS), ...
Source: Carbohydrate Polymers - Category: Biomedical Science Source Type: research
Extranodal marginal zone lymphoma of mucosa ‐associated lymphoid tissue (MALT) in the thymus is a rare disease. Furthermore, amyloid deposition in thymic MALT lymphoma has not been previously described. Here, we report a case of a 35‐year‐old man with thymic MALT lymphoma with amyloid deposition and myasthenia gravis. Chest computed tom ography revealed an anterior mediastinal mass with internal cystic component and extensive calcification. Total thymectomy was performed and histopathologic findings were compatible with a diffuse amyloid deposition in extranodal marginal zone MALT lymphoma. The results indicate that ...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
Thymic tumors are rare diseases with an incidence of 0.15 cases per 100,000 person-years. They can be associated with a variety of other syndromes, such as Myasthenia Gravis or autoimmune disorders. Among them, pure red cell aplasia is a hemato-pathological condition characterized by anemia, reticulocytopenia and erythroid cell hypoplasia of bone marrow. Here, we reported a case of a 62-year-old female with a long history of neurologic symptoms due to Myasthenia Gravis. She was diagnosed with thymoma, with mediastinal mass and pleural thickening.
Source: Transfusion and Apheresis Science - Category: Hematology Authors: Source Type: research
Jacobus Pharmaceutical Co Inc on Monday won U.S. approval for the first drug to treat children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Authors: Wang S, Breskovska I, Gandhy S, Punga AR, Guptill JT, Kaminski HJ Abstract INTRODUCTION: Myasthenia gravis (MG) is an autoimmune neuromuscular disorder with no cure and conventional treatments limited by significant adverse effects and variable benefit. In the last decade, therapeutic development has expanded based on improved understanding of autoimmunity and financial incentives for drug development in rare disease. Clinical subtypes exist based on age, gender, thymic pathology, autoantibody profile, and other poorly defined factors, such as genetics, complicate development of specific therapies. Areas cove...
Source: Expert Review of Neurotherapeutics - Category: Neurology Tags: Expert Rev Neurother Source Type: research
This article will cover the epidemiology, clinical presentation, classification, and natural history of MG.
Source: Neurologic Clinics - Category: Neurology Authors: Source Type: research
Abstract To date, more than 25 genes have been implicated in the etiology of the congenital myasthenic syndromes (CMS), and an ever‐growing phenotypic landscape is now encountered in the CMS clinic. Unlike the autoimmune form of myasthenia, there is no role for immunomodulatory agents in the treatment of CMS. The present‐day drug repertoire comprises acetylcholinesterase inhibitors (mainly pyridostigmine), 3,4‐diaminopyridine (3,4‐DAP), ephedrine, salbutamol/albuterol, open‐channel blockers (fluoxetine, quinidine), or a combination of these. These are prescribed by the specialist in an off‐label manner, as ther...
Source: Annals of the New York Academy of Sciences - Category: Science Authors: Tags: REVIEW Source Type: research
Myasthenia gravis (MG) is an autoimmune disease that causes muscle weakness through autoantibodies targeted at postsynaptic acetylcholine receptors (AchR).1,2 It is thought that there are at least 60,000 Americans living with the disease today.3 Although it is a relatively rare disease, it is not uncommon for an emergency medicine physician to have treated patients with MG. Mainstay of therapy usually includes acetylcholinesterase inhibitors, steroids, immunosuppressive therapy, and possible thymectomy.
Source: Journal of Emergency Nursing: JEN - Category: Nursing Authors: Tags: Pharm/Tox Corner Source Type: research
Conclusions eNID will ultimately increase our understanding of the epidemiology, treatment, prognosis and impact of neuroimmunological diseases through collaborative international research, leading to better patient outcomes.
Source: Journal of Neurology, Neurosurgery and Psychiatry - Category: Neurosurgery Authors: Tags: Abstracts Source Type: research
More News: Autoimmune Disease | Brain | China Health | Insurance | Internal Medicine | Myasthenia Gravis | Neurology | Rare Diseases | Study